Top

Published in:

01-04-2015 | Urologic Oncology

Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Authors: Jeremy Yuen Chun Teoh, MRCSEd, James Hok Leung Tsu, FRCSEd, FHKAM, Steffi Kar Kei Yuen, MRCSEd, Samson Yun Sang Chan, MRCSEd, Peter Ka Fung Chiu, FRCSEd, FHKAM, Wai-Man Lee, MSc, Ka-Wing Wong, MRCSEd, Kwan-Lun Ho, FRCSEd, FHKAM, Simon See Ming Hou, FHKAM, Chi-Fai Ng, FRCSEd, FHKAM, Ming-Kwong Yiu, FRCSEd, FHKAM

Published in: Annals of Surgical Oncology | Issue 4/2015

Abstract

Background

This study investigated the prognostic significance of time to the prostate-specific antigen nadir (TTPN) and its relationship to survival beyond TTPN in metastatic prostate cancer after primary androgen-deprivation therapy (ADT).

Methods

All metastatic prostate cancer patients treated with primary ADT from 2000 to 2009 were reviewed. The prognostic significance of TTPN in predicting progression-free survival (PFS) beyond TTPN and overall survival (OS) beyond TTPN was analyzed using the Cox regression model. The median PFS and OS were plotted against TTPN on a monthly interval. The PFS beyond TTPN and the OS beyond TTPN with reference to TTPN were calculated and presented.

Results

The study enrolled 419 patients with a median follow-up period of 38 months. The findings showed that TTPN was a significant prognostic indicator for both PFS beyond TTPN (hazard ratio [HR] 0.72, 95 % confidence interval [CI] 0.52–0.99, p = 0.04) and OS beyond TTPN (HR 0.65, 95 % CI 0.47–0.90, p = 0.01) according to Cox regression analyses. The relationship between TTPN and survival beyond TTPN consisted of three phases. In the first phase (<3 months for PFS and <6 months for OS), the survival beyond TTPN increased with TTPN. In the second phase (3–17 months for PFS and 6–20 months for OS), the survival beyond TTPN remained relatively static. In the third phase (>17 months for PFS and >20 months for OS), the survival beyond TTPN increased exponentially with TTPN.

Conclusions

In this study, TTPN was a good prognostic indicator for PFS beyond TTPN and OS beyond TTPN in metastatic prostate cancer cases after primary ADT. Different TTPNs had different implications for predicting survival beyond TTPN.

Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002; 168:9–12.CrossRefPubMed

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–24.CrossRefPubMed

Ablin RJ, Pfeiffer L, Gonder MJ, Soanes WA. Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg. 1969;27:406–10.PubMed

Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer. 1981;48:1229–32.CrossRefPubMed

Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013;112:548–60.CrossRefPubMed

Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol. 2011;137:235–41.CrossRefPubMed

Sasaki T, Onishi T, Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis. 2011;14:248–52.CrossRefPubMed

Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 2011;71:1189–97.CrossRefPubMed

Huang SP, Bao BY, Wu MT, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male. 2012;15:34–41.CrossRefPubMed

10.

Choueiri TK, Xie W, D’Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115:981–7.CrossRefPubMedCentralPubMed

11.

Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer. 2004;108:877–81.CrossRefPubMed

12.

Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology. 2002;59:73–8.CrossRefPubMed

13.

D’Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007;109:1290–5.CrossRefPubMed

14.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D’Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008;71:136–40.CrossRefPubMed

15.

Kitagawa Y, Ueno S, Izumi K, Mizokami A, Hinotsu S, Akaza H, Namiki M. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP). J Cancer Res Clin Oncol. 2014;140:673–9.CrossRefPubMed

Title: Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy
Authors: Jeremy Yuen Chun Teoh, MRCSEd
James Hok Leung Tsu, FRCSEd, FHKAM
Steffi Kar Kei Yuen, MRCSEd
Samson Yun Sang Chan, MRCSEd
Peter Ka Fung Chiu, FRCSEd, FHKAM
Wai-Man Lee, MSc
Ka-Wing Wong, MRCSEd
Kwan-Lun Ho, FRCSEd, FHKAM
Simon See Ming Hou, FHKAM
Chi-Fai Ng, FRCSEd, FHKAM
Ming-Kwong Yiu, FRCSEd, FHKAM
Publication date: 01-04-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 4/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-4105-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Staging Studies for Cutaneous Melanoma in the United States: A Population-Based Analysis

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer

Clinical Features and Outcome of Primary Pancreatic Lymphoma

Elective Neck Dissection in Patients With Head and Neck Adenoid Cystic Carcinoma: An International Collaborative Study

Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes